Sanofi France is staying the course! The pharmaceutical group announced, through its president Olivier Bogillot, this Tuesday October 13 to the microphone of our colleagues of Francetvinfo that a vaccine would be available in the middle of the year 2021 and that the production of this one would be engaged before the results of the phase 3 of the clinical trials in progress, betting on its viability. "Our goal is to arrive at Sanofi with a vaccine by the middle of next year. We're accelerating everything," he explains.
The vaccine is currently in phase 2 testing, and those results are expected as early as December 2020. But that doesn't stop Sanofi from taking the lead:"Once we have the phase 2 results, which are expected in December, without even waiting for the phase 3 results, which will be available in April-May of next year, we will launch production," says Olivier Bogillot. Why such an early launch of vaccine production? The president of Sanofi France also gives an answer: "simply because once we have the results of phase 3, if they are good, we will have gained at least that much time to be able to make the vaccine available," he stresses.
The availability of the vaccine by 2021 had already been mentioned by the teams of the French laboratory Sanofi, who indicated last June that they were well placed to produce a reliable vaccine against Covid-19, which would be available in large quantities. The date had even been set for early 2021.
The first clinical trial is being developed in partnership with the other British laboratory GSK, which uses the so-called DNA technology. This advance, already used in the making of the flu vaccine, was the subject of clinical trials in September. A slightly earlier date than previously announced by the laboratory. The idea is to produce up to one billion doses per year.
At the same time, other laboratories are also advancing in the search for a vaccine against Covid-19, which continues to ravage much of humanity. Moderna, an American laboratory, announced it was entering its third phase in July. Also in the pipeline are the German company CureVac's vaccine, which is in Phase 2 clinical trials,AstraZeneca's vaccine, which is well under development, China's Sinovac, and the vaccine being jointly developed by Pfizer and BioNTech.
